The Phosphodiesterase 9 Inhibitor PF-04449613 Promotes Dendritic Spine Formation and Performance Improvement after Motor Learning

Developmental Neurobiology
Baoling LaiWen-Biao Gan

Abstract

The cyclic nucleotide cGMP is an intracellular second messenger with important roles in neuronal functions and animals' behaviors. The phosphodiesterases (PDEs) are a family of enzymes that hydrolyze the second messengers cGMP and cAMP. Inhibition of phosphodiesterase 9 (PDE9), a main isoform of PDEs hydrolyzing cGMP, has been shown to improve learning and memory as well as cognitive function in rodents. However, the role of PDE9 in regulating neuronal structure and function in vivo remains unclear. Here we used in vivo two-photon microscopy to investigate the effect of a selective PDE9 inhibitor PF-04449613 on the activity and plasticity of dendritic spines of layer V pyramidal neurons in the mouse primary motor cortex. We found that administration of PF-04449613 increased calcium activity of dendrites and dendritic spines of layer V pyramidal neurons in mice under resting and running conditions. Chronic treatment of PF-04449613 over weeks increased dendritic spine formation and elimination under basal conditions. Furthermore, PF-04449613 treatment over 1-7 days increased the formation and survival of new spines as well as performance improvement after rotarod motor training. Taken together, our studies suggest that elevating ...Continue Reading

References

Feb 1, 1991·Trends in Neurosciences·J Garthwaite
Aug 10, 1990·European Journal of Pharmacology·S J East, J Garthwaite
Mar 1, 1983·The British Journal of Psychiatry : the Journal of Mental Science·W F GattazH Beckmann
Aug 18, 1993·Biochimica Et Biophysica Acta·H H SchmidtU Walter
Aug 14, 1997·Nature·K M KendrickS Ohkura
Jun 23, 1998·The Journal of Biological Chemistry·D A FisherJ B Cheng
Sep 16, 1999·Critical Reviews in Clinical Laboratory Sciences·S H Francis, J D Corbin
Dec 26, 2001·Trends in Endocrinology and Metabolism : TEM·Celine MehatsMarco Conti
Feb 9, 2002·European Journal of Pharmacology·Jos PrickaertsArjan Blokland
Dec 20, 2002·Nature·Jaime GrutzendlerWen-Biao Gan
Sep 23, 2003·Journal of Neurocytology·W C G van StaverenJ de Vente
Nov 19, 2003·The Journal of Comparative Neurology·Wilma C G Van StaverenJan De Vente
Sep 14, 2006·Pharmacological Reviews·Andrew T Bender, Joseph A Beavo
Jun 8, 2007·The European Journal of Neuroscience·Elisabet Reyes-IrisarriJan de Vente
Nov 23, 2007·Neuron·Yafell SerulleEdward B Ziff
Aug 5, 2008·Neuropharmacology·F Josef van der StaayMartin Hendrix
Aug 19, 2008·Psychopharmacology·Olga A H ReneerkensJos Prickaerts
Aug 30, 2008·Neuropsychiatric Disease and Treatment·Daniela PuzzoAgostino Palmeri
Sep 2, 2008·Proceedings of the National Academy of Sciences of the United States of America·Shenping LiuFrank S Menniti
Oct 30, 2008·European Journal of Pharmacology·Eva L van DonkelaarJos Prickaerts
Jul 25, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Feras TaqatqehThomas Mittmann
Feb 20, 2010·Current Topics in Medicinal Chemistry·Christopher J Schmidt
Mar 10, 2010·Molecular Neurobiology·Katarzyna Urszula Domek-Łopacińska, Joanna B Strosznajder
Sep 10, 2010·British Journal of Pharmacology·Masayuki HiramatsuHiromasa Mori
Jun 9, 2011·British Journal of Pharmacology·O BrunoR Ricciarelli
Feb 14, 2012·The Journal of Pharmacology and Experimental Therapeutics·Robin J KleimanChristopher J Schmidt

❮ Previous
Next ❯

Citations

Feb 15, 2020·Journal of Affective Disorders·Eduardo Duarte-SilvaChristina Peixoto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.